Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma

Hill, Mark; Constenla, D.; A’Hern, Roger; Henk, J.M.; Rhys‐Evans, Peter; Breach, N. M.; Archer, Daniel J.; Gore, Martin

doi:10.1016/s0964-1955(97)00026-2

Cited by 67 publications

(31 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The response rates of ACC to conventional cytotoxic chemotherapy such as cisplatin, 5-fluorouracil, epirubicin and antracyclines have been generally modest (Verweij et al 1996;Hill et al 1997;Vermorken et al 1993). There is only little information on the factors promoting distant metastasis.…”

Section: Discussionmentioning

confidence: 99%

Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis

Teymoortash

Pientka

Schrader³

et al. 2005

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis

Teymoortash

Pientka

Schrader³

et al. 2005

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…The use of chemotherapy in AdCC is controversial. Some investigators have reported positive responses to chemotherapy and recommended it as palliative therapy in advanced cases [16].…”

Section: Dıscussionmentioning

confidence: 99%

Unique presentation of adenoid cystic carcinoma in postcricoid region: a case report and review of the literature

Saraydaroğlu

Çoşkun

Kasap

2011

Head and Neck Pathol

View full text Add to dashboard Cite

Malignant tumors of minor salivary glands are uncommon, representing only 2-4% of all head and neck malignancies. In the larynx, minor salivary gland tumors rarely occur and constitute less than 1% of laryngeal tumors. Most of the minor salivary gland tumors arise in the subglottis; however, they can also occur in the supraglottis in the false vocal cords, aryepiglottic folds, and caudal aspect of the epiglottis. The most common type of malignant minor salivary gland tumor is adenoid cystic carcinoma. In the last 20 years, only 40 cases of adenoid cystic carcinoma arising in variable locations of the larynx have been reported in the English language literature. We present a case of adenoid cystic carcinoma of the larynx arising in the inter-arytenoid and postcricoid region in a 54-year-old woman. To our knowledge, this is the first case of adenoid cystic carcinoma arising in this particular region of the larynx.

show abstract

“…With respect to clinical response, the RECIST criteria were applied to visible or palpable areas of disease and CR, PR, SD or PD was recorded. In addition, an assessment of symptomatic response was made using a four-point scale previously reported in adenoid cystic carcinoma and non-small-cell lung cancer (Hardy et al, 1989;Hill et al, 1997). In this scale, individual symptoms were documented prior to treatment, and at subsequent assessment each symptom was recorded as being either (a) worse, (b) unchanged, (c) improved or (d) resolved.…”

Section: Response Assessmentmentioning

confidence: 99%

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer

et al. 2006

View full text Add to dashboard Cite

To assess the level of activity and toxicity of gefitinib (ZD1839, Iressat) in a population of patients with locally recurrent and/or metastatic head and neck cancer. Patients were recruited into an expanded access programme through the multidisciplinary head and neck clinics at the Royal Marsden and St George's Hospitals. Patients were required to have received at least one course of standard systemic chemotherapy or radiation therapy, or be medically unfit for chemotherapy. Patients were commenced on single-agent gefitinib at a dose of 500 mg day À1 . Clinical, symptomatic and radiological response, time to progression (TTP), survival and toxicity were recorded. A total of 47 patients were enrolled (35 male and 12 female) with a median age of 62 years (range 18 -93 years). The observed clinical response rate was 8% with a disease control rate (complete response, partial response, stable disease) of 36%. In all, 34% of patients experienced an improvement in their symptoms. The median TTP and survival were 2.6 and 4.3 months, respectively. Acneiform folliculitis was the most frequent toxicity observed (76%) but the majority of cases were grade 1 or 2. Only four patients experienced grade 3 toxicity of any type (all cases of folliculitis). Gefitinib was well tolerated and yielded symptomatic improvement in one-third of patients. However, this agent appeared to possess limited antitumour activity in this group of patients with head and neck cancer in whom the objective response rate, median TTP and survival were all lower than has been reported in a previous study.

show abstract

Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma

Cited by 67 publications

References 24 publications

Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis

Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis

Unique presentation of adenoid cystic carcinoma in postcricoid region: a case report and review of the literature

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer

Contact Info

Product

Resources

About